Company intelligence / Profile preview

Kangling Medical

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

KL003 demonstrated 100% efficacy in 17 beta thalassemia patients in Phase 1/IIT, with favorable safety, shorter time to transfusion independence, and reduced manufacturing costs; Phase 2 pivotal trial planned for 2025.

Therapeutic areas: Hematology
Modalities: Gene therapyLentiviral vector gene therapyHematopoietic stem cell therapyAAV based gene therapy
Industry: Biotech

Beyond the preview

Go deeper on Kangling Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kangling Medical.

Explore the full profile